Arnold Ganser

Research interests

Publications

• Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

  Bone Marrow Transplantation · 2020 · https://doi.org/10.1038/s41409-020-0803-y

• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

  Blood · 2017 · https://doi.org/10.1182/blood-2016-06-724500

• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1614359

• Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.67.1982

• Genomic Classification and Prognosis in Acute Myeloid Leukemia

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1516192

• Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation

  Blood · 2014 · 10.1182/blood-2014-05-578070

• Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300874

• Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

  Blood · 2012 · 10.1182/blood-2011-09-377713

• Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

  Blood · 2012 · 10.1182/blood-2011-12-399337

• Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.35.4894

• Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.30.9245

• A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

  Blood · 2011 · https://doi.org/10.1182/blood-2011-01-330126

• TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

  Blood · 2011 · 10.1182/blood-2011-08-375758

• RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.30.7926

• Monitoring of Minimal Residual Disease in NPM1 -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.35.0371

• Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1000067

• Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease

  Molecular & Cellular Proteomics · 2010 · 10.1074/mcp.m110.001917

• The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

  Blood · 2010 · 10.1182/blood-2010-08-301713

• Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

  Blood · 2010 · 10.1182/blood-2010-09-307280

• Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70074-9

• Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

  New England Journal of Medicine · 2008 · 10.1056/nejmoa074306

• Intracoronary Bone Marrow Cell Transfer After Myocardial Infarction

  Circulation · 2006 · 10.1161/circulationaha.105.575118

• Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation

  Nature Genetics · 2006 · 10.1038/ng1937

• Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium

  Circulation · 2005 · 10.1161/01.cir.0000163546.27639.aa

• Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial

  The Lancet · 2004 · 10.1016/s0140-6736(04)16626-9

• Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults

  Blood · 1988 · 10.1182/blood.v71.1.123.123

Current projects

No projects listed.